CN107184600A - 一种含有无机砷化合物的药物组合物及其应用 - Google Patents
一种含有无机砷化合物的药物组合物及其应用 Download PDFInfo
- Publication number
- CN107184600A CN107184600A CN201710385867.7A CN201710385867A CN107184600A CN 107184600 A CN107184600 A CN 107184600A CN 201710385867 A CN201710385867 A CN 201710385867A CN 107184600 A CN107184600 A CN 107184600A
- Authority
- CN
- China
- Prior art keywords
- cancer
- pharmaceutical composition
- carcinoma
- niclosamide
- inorganic arsenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- 229910052785 arsenic Inorganic materials 0.000 title claims description 4
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 title claims description 4
- 239000000126 substance Substances 0.000 title description 3
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 claims abstract description 35
- 229960001920 niclosamide Drugs 0.000 claims abstract description 33
- 150000001495 arsenic compounds Chemical class 0.000 claims abstract description 19
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 12
- 201000011510 cancer Diseases 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 8
- PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 claims description 23
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010000830 Acute leukaemia Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 201000011603 cardia cancer Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000024207 chronic leukemia Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000003956 middle ear cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 claims 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 1
- 201000005746 Pituitary adenoma Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000022033 carcinoma of urethra Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000003914 endometrial carcinoma Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 1
- 208000020717 oral cavity carcinoma Diseases 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
- 229940097322 potassium arsenite Drugs 0.000 claims 1
- HEQWEGCSZXMIJQ-UHFFFAOYSA-M potassium;oxoarsinite Chemical compound [K+].[O-][As]=O HEQWEGCSZXMIJQ-UHFFFAOYSA-M 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000002700 inhibitory effect on cancer Effects 0.000 abstract description 3
- 231100000057 systemic toxicity Toxicity 0.000 abstract description 3
- 230000002147 killing effect Effects 0.000 abstract description 2
- 238000011287 therapeutic dose Methods 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 8
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 229940000425 combination drug Drugs 0.000 description 3
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 108091007417 HOX transcript antisense RNA Proteins 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- -1 inorganic compound arsenic trioxide Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008844 regulatory mechanism Effects 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- GCPXMJHSNVMWNM-UHFFFAOYSA-N arsenous acid Chemical compound O[As](O)O GCPXMJHSNVMWNM-UHFFFAOYSA-N 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- KTTMEOWBIWLMSE-UHFFFAOYSA-N diarsenic trioxide Chemical compound O1[As](O2)O[As]3O[As]1O[As]2O3 KTTMEOWBIWLMSE-UHFFFAOYSA-N 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000005459 gum cancer Diseases 0.000 description 1
- 229940093920 gynecological arsenic compound Drugs 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 201000000360 urethra cancer Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种含有Niclosamide与无机砷化合物的药物组合物及其应用，该药物组合物含有无机砷化合物和Niclosamide，用于制备癌症治疗药物。Niclosamide又名氯硝柳胺分子式为 C13H8Cl2N2O4，CAS号CAS:50‑65‑7。该药物组合物，对于癌症细胞的杀灭作用强于单独使用无机砷化合物，同时也强于单独使用Niclosamide。本发明使得无机砷化合物的治疗剂量降低，对癌症的抑制效果增强，有效地降低了无机砷化合物的系统性毒性。
Description
技术领域
本发明涉及一种含有Niclosamide与无机砷化合物的药物组合物及其应用，具体涉及一种含有无机砷化合物与Niclosamide的药物组合物，及其在制备用于治疗癌症药物中的应用。
背景技术
1971 年，哈尔滨医学院第一附属医院的韩太云将含有砒霜的中药改造研制成治疗白血病的药物。1973年，张亭栋、张鹏等应用″ 癌灵一号″ 治疗慢性粒细胞白血病，使患者血液学指标和临床症状得到改善。已经证明无机化合物三氧化二砷可以治疗复发性或顽固性急性早幼粒细胞白血病 (APL)，近来初步数据表明三氧化二砷在其他癌症中也具有作用, 因此研究三氧化二砷作为抗癌药是抗癌药物的热点之一。但是三氧化二砷的全身毒性是一个严重问题，严重影响的抗癌的应用，因此需要进一步研究，有效降低砷的毒副作用，提高抗癌疗效。课题组在云南省科技计划项目-面上项目三氧化二砷对HOTAIR基因表达的表观遗传调控机制研究（受理编号201601CH00019）资助下对三氧化二砷进行进一步研究。
Niclosamide 中文名氯硝柳胺又名灭绦灵分子式为 C13H8Cl2N2O4 CAS:50657 对多种有钩及无钩绦虫均有效果 。
发明内容
本发明的目的在于提供一种含有Niclosamide与无机砷化合物的药物组合物及其应用。
本发明的目的是这样实现的：
一种药物组合物由三价无机砷化合物与Niclosamide组成作为活性成分或者是药用载体。三价无机砷化合物与Niclosamide的摩尔比是1:2-2:1之间。三价无机砷化合物是三氧化二砷或者亚砷酸或者亚砷酸化合物，例如亚砷酸钠。上述的药物组合物在制备治疗癌症的药物中的应用。所述癌症包括 ：肝癌、肺癌、胰腺癌、乳腺癌、宫颈癌、子宫内膜癌、大肠癌、胃癌、肾癌、鼻咽癌、卵巢癌、前列腺癌症、慢性或急性白血病、脑瘤、食道癌、口腔癌、贲门癌、结肠癌、胆囊癌、喉癌、牙龈癌、尿道癌、皮肤癌、直肠癌、中耳癌、骨癌、 睾丸癌、内分泌系统的癌症、淋巴细胞性淋巴瘤、原发性 CNS 淋巴瘤、脊柱轴肿瘤垂体腺瘤，特别是肺癌。
本发明优点：
1.本发明中的药物组合物，对于癌症细胞的抑制作用强于单独使用无机砷化合物，同时也强于单独使用Niclosamide。
2.本发明使得无机砷化合物的治疗剂量降低，对癌症的抑制效果增强，有效地降低了无机砷化合物的系统性毒性，使其应用变得更加安全。
附图说明
图1：Niclosamide的结构式。
具体实施方式
下面对本发明作进一步的说明，但不以任何方式对本发明加以限制，基于本发明所作的任何变换，均属于本发明的保护范围。
实施例：
取对数生长期的肺癌细胞A549或者XWLC-05细胞接种于96孔板，将亚砷酸钠溶于pbs中，每孔1000个细胞。置CO2培养箱中37℃孵育24小时后加入样品。对照组加入10μL PBS溶液；亚砷酸钠组加入10μL亚砷酸钠溶液；Niclosamide组10μL受试物溶液，联合用药组加入5μL受试物溶液与5μL亚砷酸钠溶液。其中亚砷酸钠和Niclosamide的终浓度分别为μmol L-1，每组设6复孔，每个实验分别重复3次。放入37℃ CO2培养箱中。5天后加入20 μL MTS溶液，37℃ CO2培养箱中继续孵育2小时，用全自动酶标仪在490nm测定吸光度(A)。以上均在 云南省科技计划项目-面上项目三氧化二砷对HOTAIR基因表达的表观遗传调控机制研究（受理编号201601CH00019）资助下完成。
具体结果为
亚砷酸钠与Niclosamide联合对A549细胞的作用
联合用药组1：亚砷酸钠0.5uM + Niclosamide 0.5uM
联合用药组2：亚砷酸钠0.5uM + Niclosamide 1uM
联合用药组3：亚砷酸钠1uM + Niclosamide 0.5uM
联合用药组4：亚砷酸钠1uM + Niclosamide 1uM
*与对照组、亚砷酸钠0.5uM、亚砷酸钠1 uM、亚砷酸钠2 uM、Niclosamide 0.5uM、Niclosamide 1uM、Niclosamide 2uM7个组比较均p<0.05
亚砷酸钠与Niclosamide 联合对XWLC-05细胞的作用
联合用药组1：亚砷酸钠1uM + Niclosamide 0.5uM
联合用药组2：亚砷酸钠1uM + Niclosamide 1uM
联合用药组3：亚砷酸钠2uM + Niclosamide 0.5uM
联合用药组4：亚砷酸钠2uM + Niclosamide 1uM
*与对照组、亚砷酸钠1uM、亚砷酸钠2 uM、亚砷酸钠4 uM、Niclosamide 0.5uM、Niclosamide 1uM、Niclosamide 2uM7个组比较均p<0.05
从表中可以看出联合用药组对肿瘤细胞的杀灭作用优于单独使用。
Claims (8)
1.一种药物组合物，其特征是由三价无机砷化合物与Niclosamide组成作为活性成分或者是药用载体。
2.根据权利要求1所述的药物组合物，其特征是所述的三价无机砷化合物与Niclosamide的摩尔比是1:2-2:1之间。
3.根据权利要求1所述的药物组合物，其特征是所述的三价无机砷化合物是三氧化二砷。
4.根据权利要求1所述的药物组合物，其特征是所述的三价无机砷化合物是亚砷酸化合物。
5.根据权利要求4所述的药物组合物，其特征是所述的三价无机砷化合物是亚砷酸钠、亚砷酸钾的一种。
6.权利要求1~5任一项的所述的药物组合物在制备治疗癌症的药物中的应用。
7.根据权利要求6所述的应用，其中所述癌症包括 ：肝癌、肺癌、胰腺癌、乳腺癌、宫颈癌、子宫内膜癌、大肠癌、胃癌、肾癌、鼻咽癌、卵巢癌、前列腺癌症、慢性或急性白血病、脑瘤、食道癌、口腔癌、贲门癌、结肠癌、胆囊癌、喉癌、牙龈癌、尿道癌、皮肤癌、直肠癌、中耳癌、骨癌、 睾丸癌、内分泌系统的癌症、淋巴细胞性淋巴瘤、原发性 CNS 淋巴瘤、脊柱轴肿瘤垂体腺瘤。
8.根据权利要求7的应用，其中所述癌症是肺癌。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710385867.7A CN107184600B (zh) | 2017-05-26 | 2017-05-26 | 一种含有无机砷化合物的药物组合物及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710385867.7A CN107184600B (zh) | 2017-05-26 | 2017-05-26 | 一种含有无机砷化合物的药物组合物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107184600A true CN107184600A (zh) | 2017-09-22 |
| CN107184600B CN107184600B (zh) | 2020-02-21 |
Family
ID=59875118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710385867.7A Expired - Fee Related CN107184600B (zh) | 2017-05-26 | 2017-05-26 | 一种含有无机砷化合物的药物组合物及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107184600B (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111118011A (zh) * | 2020-02-11 | 2020-05-08 | 昆明医科大学 | 一种抑制hsa_circ_0027478表达的siRNA及其应用 |
| CN111647598A (zh) * | 2020-02-11 | 2020-09-11 | 昆明医科大学 | 一种抑制hsa_circ_0027477表达的siRNA及其应用 |
| CN111733158A (zh) * | 2020-02-11 | 2020-10-02 | 昆明医科大学 | 一种抑制hsa_circ_0003599表达的siRNA及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009148623A2 (en) * | 2008-06-05 | 2009-12-10 | Stc.Unm | Methods and related compositions for the treatment of cancer |
-
2017
- 2017-05-26 CN CN201710385867.7A patent/CN107184600B/zh not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009148623A2 (en) * | 2008-06-05 | 2009-12-10 | Stc.Unm | Methods and related compositions for the treatment of cancer |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111118011A (zh) * | 2020-02-11 | 2020-05-08 | 昆明医科大学 | 一种抑制hsa_circ_0027478表达的siRNA及其应用 |
| CN111647598A (zh) * | 2020-02-11 | 2020-09-11 | 昆明医科大学 | 一种抑制hsa_circ_0027477表达的siRNA及其应用 |
| CN111733158A (zh) * | 2020-02-11 | 2020-10-02 | 昆明医科大学 | 一种抑制hsa_circ_0003599表达的siRNA及其应用 |
| CN111118011B (zh) * | 2020-02-11 | 2022-09-06 | 昆明医科大学 | 一种抑制hsa_circ_0027478表达的siRNA及其应用 |
| CN111733158B (zh) * | 2020-02-11 | 2022-09-06 | 昆明医科大学 | 一种抑制hsa_circ_0003599表达的siRNA及其应用 |
| CN111647598B (zh) * | 2020-02-11 | 2022-09-06 | 昆明医科大学 | 一种抑制hsa_circ_0027477表达的siRNA及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107184600B (zh) | 2020-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brown et al. | Cisplatin-based chemotherapy of human cancers | |
| CN106214698A (zh) | 一种含有无机砷化合物的药物组合物及其应用 | |
| CN109549954B (zh) | 一种磷基材料制剂及其制备方法和应用 | |
| CN102357100A (zh) | 抗肿瘤联合药物 | |
| CN107184600B (zh) | 一种含有无机砷化合物的药物组合物及其应用 | |
| Shaaban et al. | Organoselenium-based azomethines as apoptosis inducers in colorectal carcinoma via P53, BAX, caspase-3, caspase-6, and caspase-9 modulations | |
| Chaudhary et al. | Combinatorial effect of arsenic and herbal compounds in telomerase-mediated apoptosis induction in liver cancer | |
| CN114748480A (zh) | 一种预防和/或治疗癌症的药物组合物 | |
| EP4412607A1 (en) | Combination therapies using prmt5 inhibitors for the treatment of cancer | |
| CN110522753A (zh) | 一种新型抗肿瘤药物组合物、制剂和应用 | |
| CN107115355B (zh) | 一种含有无机砷化合物的药物组合物及其应用 | |
| KR20140035974A (ko) | 종양 질환 치료를 위한 약제 조성물 | |
| CN114469963B (zh) | 格列喹酮与顺铂联合用药在制备抗肿瘤药物中的应用 | |
| CN107158399B (zh) | 两亲性纳米药物及其制备方法和应用 | |
| JP5202332B2 (ja) | がんの治療のための化合物および方法 | |
| CN110151748A (zh) | 一种用于治疗前列腺癌的药物组合物 | |
| CN115322226A (zh) | 一种共价靶向砷抑制剂及其制备方法和应用 | |
| CN104146999B (zh) | 冬凌草甲素和多烯紫杉醇减毒增效抗肿瘤药物组合物及其应用 | |
| CN103483187B (zh) | 4-乙氧基-2-羟基-6-甲基苯甲酸及其药用组合物和应用 | |
| CN106668061B (zh) | 一种含有顺铂的抗癌药物组合物 | |
| CN104774213B (zh) | 具有抗炎活性的双氯芬酸锌配合物及其制备方法 | |
| CN105263499A (zh) | 用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合 | |
| CN101836992A (zh) | 4-苯并噻酚氨基喹唑啉衍生物在制备治疗肿瘤药物方面的应用 | |
| CN109602742A (zh) | 咯萘啶在制备用于诱导细胞凋亡的药物及抗乳腺癌药物中的用途 | |
| Chen et al. | Inhibition of autophagy enhances SMI-4a-induced growth inhibition and apoptosis of melanoma cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200630 Address after: Nansha District Fengze road Guangzhou city Guangdong province 510000 No. 106 Patentee after: Guangzhou Xuxin Information Technology Service Co.,Ltd. Address before: 650000, Kunming, Yunnan Province, Chenggong Metro Street, No. 1168, spring melts West Road Patentee before: KUNMING MEDICAL University |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201105 Address after: Room 603, building 6, No. 999, Wanshou South Road, Chengnan street, Rugao City, Nantong City, Jiangsu Province Patentee after: Nantong Guang Heng Biotechnology Co.,Ltd. Address before: Nansha District Fengze road Guangzhou city Guangdong province 510000 No. 106 Patentee before: Guangzhou Xuxin Information Technology Service Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221228 Address after: 252000 Building C8, Xinxing Industrial Park, southeast corner of the intersection of Wuxun Avenue and North Ring Road, Chongwen Street, Guanxian County, Liaocheng City, Shandong Province Patentee after: Zhongzhitang Pharmaceutical (Shandong) Co.,Ltd. Address before: Room 603, building 6, 999 Wanshou South Road, Chengnan street, Rugao City, Nantong City, Jiangsu Province, 226500 Patentee before: Nantong Guang Heng Biotechnology Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200221 |